Navigation Links
Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology
Date:5/20/2010

SAN DIEGO, May 20 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern. Sequestering agents, such as antibodies, are used to immobilize the cells in the cavity of the device. Cells can then be analyzed inside the microchannel using morphological, immunohistochemical, or fluorescent in situ hybridization (FISH) tests, or the cells can be released from the channel for molecular analysis following extraction of DNA.

"This patent establishes Biocept's leadership position in using a microfluidic device to capture and analyze rare cells for prenatal or cancer applications," said Stephen M. Coutts, President and CEO of Biocept. "We are using this invention to develop innovative proprietary tests in which we capture and analyze circulating tumor cells from a blood sample from cancer patients. These circulating tumor cells provide genetic information about the patient's disease and can potentially guide the clinicians in making therapeutic choices to maximize patient response. We look forward to bringing this technology through to commercialization and making personalized medicine a reality for cancer patients and their families."

About Biocept

Biocept, whose focus is in cell separation technology, develops novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. Biocept's CEE™ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... The National University of Singapore (NUS) ... company, signed a Memorandum of Understanding (MOU) recently ... the region. Under this MOU, ... Technology (BIGHEART) at NUS and Holmusk will establish ... healthcare IT and medical device development. These include ...
(Date:3/27/2017)... 2017  A recent study at Shriners Hospitals for ... in the country dedicated to the treatment of pediatric ... that the Surfacide Helios ® UV-C Disinfection System ... bacterial pathogens not killed by the EVS (manual) cleaning ... American Burn Association,s 49th Annual Meeting in ...
(Date:3/27/2017)... Germany , March 27, 2017 ... over 7,000 attendees and more than 600 exhibitors ... and discover opportunities and solutions that will advance ... 6 April 2017 at the Messe Stuttgart, ... the preeminent medical technology platform showcasing the key ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... by the American Association of Integrative Medicine and available for application on Saturday, ... the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president of AutismOne, ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot this ... of professional staff discussed strategies for preventing outbreaks among camp communities during the ...
(Date:3/28/2017)... ... ... a common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. ... of dealing with excess skin oil. “Oily skin is a challenge to many of my ... the oily shine while keeping the skin fresh and clean,” says Dr. Au. , What ...
(Date:3/28/2017)... ... ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets ... parents and teachers had asked of him that he had neglected to do, but this ... Almighty Creator. There were some who would have felt themselves to be special and better ...
(Date:3/27/2017)... ... 27, 2017 , ... The respected dental team at Northwood ... without the extensive time commitment and aesthetic disadvantages of traditional braces can now ... custom-designed series of virtually invisible aligners are created for each patient and crafted ...
Breaking Medicine News(10 mins):